Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice

BACKGROUND: The use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) could affect COVID-19 outcomes by modulating the immune response, which, in turn, might favor viral replication and/or confer protection from COVID-19 induced inflammatory response CASE REPORT: We report on two MS p...

Descripción completa

Detalles Bibliográficos
Autores principales: De Angelis, Marcello, Petracca, Maria, Lanzillo, Roberta, Brescia Morra, Vincenzo, Moccia, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428688/
https://www.ncbi.nlm.nih.gov/pubmed/32823148
http://dx.doi.org/10.1016/j.msard.2020.102452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428688/
https://www.ncbi.nlm.nih.gov/pubmed/32823148
http://dx.doi.org/10.1016/j.msard.2020.102452

Ejemplares similares